Background: Electrochemotherapy is an antitumor therapy that utilizes locally-delivered, short intense direct current electric pulse to the tumor nodule plus chemotherapy. The aim of the present study was to evaluate the electrochemotherapy treatment of perianal tumors of different sizes in dogs.
Materials And Methods: In 12 dogs, 26 tumor nodules of perianal tumors of different size, and clinically expected to be of different histological type, were treated with electrochemotherapy. Electrochemotherapy consisted of intratumoral injection of cisplatin (1 mg/cm3) or bleomycin (3 mg/cm3), followed by application of electric pulses (8 electric pulses; amplitude, 910 V, duration, 100 micros, frequency, 1 Hz) to the tumor nodule.
Results: Responses to treatment were assessed 4 weeks after the therapy; 82% of all tumors treated with electrochemotherapy responded with objective response (OR) (complete response (CR)=41%, partial response (PR)=41%), 16% responded with no change (NC) and 1 tumor (2%) went to progressive disease (PD). At the end of the observation period for each tumor, ranging from 1 to 34 months, 92% OR (CR=65%, PR=27%), 8% NC and no PD were obtained. No major local or general side-effects were noted.
Conclusion: Electrochemotherapy with cisplatin or bleomycin is an effective treatment of perianal tumors in dogs. The advantages of this therapy are its simplicity, short duration of treatment sessions, low chemotherapeutic doses and insignificant side-effects, as well as the fact that the subject does not have to stay in hospital.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry.
Inflamm Bowel Dis
January 2025
Division of Gastroenterology, University of California, San Francisco, San Francisco, CA, USA.
Background: Women with inflammatory bowel disease (IBD) face complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for perianal disease and perineal trauma. The incidence of poor wound healing after obstetric anal sphincter injury is approximately 4% in the general population.
View Article and Find Full Text PDFImpact of biologics on stoma creation and reversal in Crohn's disease: a retrospective analysis from 2007 to 2021.
Tech Coloproctol
January 2025
Department of General Surgery, Jinling Hospital, Nanjing Medical University, No. 305 East Zhongshan Rd, Nanjing, 210002, People's Republic of China.
Background: Trends of stoma creation at index surgery for Crohn's disease (CD) in the biologics era has not been thoroughly investigated. This study aimed to assess the impact of increasing biologics use on stoma rates at index surgery of CD, as well as identifying risk factors for the creation and nonreversal of CD-related stoma.
Methods: In this single-center retrospective analysis, consecutive CD patients who underwent index bowel surgery from 2007 to 2021 were reviewed.
Primary perianal alveolar rhabdomyosarcoma with uncommon metastatic sites: a case report and follow-up using F-FDG PET/CT.
Front Med (Lausanne)
December 2024
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Article Synopsis
- Rhabdomyosarcoma (RMS) is a rare and aggressive pediatric cancer that commonly affects children and adolescents, with alveolar rhabdomyosarcoma (ARMS) often developing in areas like the trunk and head/neck.
- An 11-year-old girl diagnosed with ARMS presented with a perianal mass, showing aggressive metastasis to the pleura, lymph nodes, and even bones, which is less common.
- The case underscores the difficulties in diagnosing and treating ARMS, stressing the importance of early detection, advanced imaging techniques, and the need for ongoing research to develop better treatment options.
Early intervention with Ustekinumab is associated with higher rates of clinical and endoscopic remission in patients with Crohn's disease.
Therap Adv Gastroenterol
December 2024
Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
Background: Early biologic intervention after diagnosis has shown improved clinical and endoscopic outcomes in patients with Crohn's disease (CD), while very little is known about the effectiveness of early versus late administration of Ustekinumab (UST).
Objectives: We aimed to compare early versus late UST use in managing CD and identify potential predictors associated with clinical and endoscopic outcomes.
Design: This was a retrospective observational study.
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.
Therap Adv Gastroenterol
December 2024
Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani, 2, Padua 35128, Italy.
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!